drugset / Trial / NCT02561455
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
NaParallel-groupOpen-labelTreatment
Summary
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.
Timeline
- Start
- 2016-05-03
- Primary completion
- 2020-07-28
- Completion
- 2020-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gilteritinib | Small molecule | 40 mg | Oral |
| Subject | Gilteritinib | Small molecule | 80 mg | Oral |
| Subject | Gilteritinib | Small molecule | 120 mg | Oral |
| Subject | Gilteritinib | Small molecule | 200 mg | Oral |